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ABSTRACT 
Data on antiretroviral therapy (ART) adherence among prison inmates are limited and not previously 
synthesised in a systematic manner. The objective of this study was to provide accurate and up-to-date 
ART adherence estimates among prison inmates. We searched electronic databases for all studies 
reporting adherence as a primary or secondary outcome among prison inmates. A random-effects 
model was used to pool adherence rates;  sensitivity, heterogeneity, and publication bias were 
assessed. Eleven studies involving 2,895 HIV-infected prison inmates were included. The studies were 
carried out between 1992 and 2011 and reported between 1998 and 2013. A pooled analysis of all 
studies indicated a pooled estimate of 54.6% (95% confidence interval 48.1 – 60.9%) of prison inmates 
had adequate (≥95%) ART adherence.  The adherence estimates were significantly higher among 
cross-studies and studies that used self-reported measures. In summary, our findings indicate that 
optimal adherence remains a challenge among prison inmates. It is crucial to monitor ART adherence 
and develop appropriate interventions to improve adherence among these population.  
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INTRODUCTION 
It has been documented that there is a higher burden of HIV infection among incarcerated populations 
in low-, middle, and high-income countries(Jurgens, Nowak, & Day, 2011) as well as its negative impact 
on continuity of care; development of trust; and, subsequently, optimal adherence(Seal, 2005). 
Incarceration provides public health opportunity to provide life-saving antiretroviral therapy (ART) to 
HIV-infected persons; but multiple barriers to ART access, delivery and adherence persist(R. Y. Chen 
et al., 2006; Hammett, Kennedy, & Kuck, 2007; Zaller, Thurmond, & Rich, 2007). Even, after release 
from prisons, non-adherence and loss-to-follow up has been reported as a major issue(Baillargeon et 
al., 2009). Of paramount importance while in prison is the necessity to maintain patient confidentiality, 
in order to avoid perceived and experienced stigma(Ines, Moralejo, Marcos, Fuertes, & Luna, 2008; 
Pontali, 2005; Rosen et al., 2004; Small, Wood, Betteridge, Montaner, & Kerr, 2009) as well as 
assisting prisoners at delivery to be linked to care in outpatient basis, maintain high level of adherence 
and re-insertion in the community(Milloy et al., 2011; Springer et al., 2004; Stephenson et al., 2005). 
There are limited knowledge on the level of achievable ART adherence in prison globally as well as 
evidence-based interventions. We therefore conducted a systematic review with meta-analysis to fill 
this research gap, to provide a more accurate and up-to-date ART adherence estimates among prison 
inmates living with HIV in order to attempt to quantify the burden and inform decision regarding policy 
responses and public health intervention.  
 
METHODS 
Protocol and Registration 
The study background, rationale, and methods were specified in advance and documented in a 
protocol to be published at the international prospective register of systematic reviews (PROSPERO; 
Number: CRD42016044044)(Uthman, Nduka, & Oladimedji, 2016). 
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Eligibility Criteria 
Type of studies: cross-sectional and cohort studies that reported ART adherence rates as a primary or 
secondary outcome. No language, publication date or publication status restrictions were imposed. We 
excluded studies that involved directly observed antiretroviral therapy. Types of participants: HIV-
infected prison inmates on ART. Types of outcome measures: adherence rates regardless of measures 
(such as self-reported, pill count, etc.). 
 
Information Sources and Search Strategy 
Two of the authors (OAU & OO) conducted searches on the following electronic databases (from 1980 
to January 2016): PubMed, EMBASE, SCI Web of Science, NLM Gateway and Google scholar. We 
used the following keywords: “prisoners”, “jail”, "adherence", “compliance”, "antiretroviral therapy" “HIV”; 
“HAART”; “ART” (see Appendix 1 for the full Medline search strategy). We searched abstract of 
relevant conference proceedings from 2006 onward (the most recent ones that may not have been 
indexed in NLM Gateway meeting abstracts). In addition, the bibliographies of relevant review articles 
and selected articles were examined for pertinent studies.   
 
Study selection 
Two authors (OAU and OO) evaluated the eligibility of studies obtained from the literature search using 
a predefined protocol, and worked independently to scan all abstracts and obtain full text of articles.  In 
cases of discrepancy, agreement was reached by consensus and by discussions with the third 
reviewer.  
 
Risk of bias assessment 
We used the the Risk of Bias Assessment Tool for Nonrandomized Studies (RoBANS)(S. Y. Kim et al., 
2013) to appraise the risk of bias for included studies(see Appendix 2). This included information on 
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the selection bias (sample population), selection bias (participation rate), performance bias (outcome 
assessment), performance bias (analytical methods to control for bias) and other form of bias. The 
methodological components of the studies were assessed and classified as adequate, inadequate or 
unclear. Where differences arose, they were resolved by discussions with the third reviewer. 
 
Data abstraction 
Two reviewers (OAU and OO) independently extracted and compared the data. For each study that 
met the selection criteria, details were extracted on study design, study population characteristics, and 
adherence measures. 
 
Data Analysis 
For the meta-analysis, we first stabilized the raw ART adherence proportions from each study using the 
Freeman-Tukey variant of the arcsine square root transformed proportion(Stuart & Ord, 1994) suitable 
for pooling. We used a DerSimonian-Laird random effects model(DerSimonian & Laird, 1986) due to 
anticipated variations in study population, health care delivery systems and epidemic course. To 
evaluate the stability of the results we applied several sensitivity analyses, including fixed effects 
analysis and used a one-study removed approach.(Normand, 1999)  The purpose of this analysis was 
to evaluate the influence of individual studies, by estimating pooled estimate in the absence of each 
study. We assessed heterogeneity among trials by inspecting the forest plots and using the chi-squared 
test for heterogeneity with a 10% level of statistical significance, and using the I2 statistic where we 
interpret a  value of 50% as representing moderate heterogeneity.(Higgins & Thompson, 2002; Higgins, 
Thompson, Deeks, & Altman, 2003) We assessed the possibility of publication bias by evaluating a 
funnel plot for asymmetry. Because graphical evaluation can be subjective, we also conducted a 
Egger’s regression asymmetry test(Egger, Davey, Schneider, & Minder, 1997) as formal statistical tests 
for publication bias. 
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The effect of the following study-level factors on the overall adherence rates was explored using sub-
group and meta-regression analyses: type of publication (full-text versus conference abstract), study 
period (earlier studies conducted before 2000 versus recent studies conducted after 2000), publication 
year, study design (cross-sectional versus cohort), study’s region (North America, Europe & sub-
Saharan Africa), study size (small:<150 versus large: 150 plus), adherence threshold (≥95% versus 
100%), adherence measures (self-reported versus pharmacy refill). Series of univariable random-
effects meta-regression analyses were conducted to investigate the impact of factors on the pooled 
adherence proportions. Meta-analysis results were reported as combined adherence proportions with 
95% confidence intervals (CIs), while meta-regression results are reported as odds ratio with 95% CIs. 
We assessed the level of agreement between the review authors reviewers using kappa analysis and 
reported using the Cohen kappa index (Cohen, 1960). All p-values were exact and p-value less the 
0.050 was considered statistically significant. Analyses were conducted using Stata version 14 for 
Windows (Stata Corp, College Station, Texas). This systematic review was reported according to the 
Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines 
(http://www.prisma-statement.org).(Liberati et al., 2009; Moher, Liberati, Tetzlaff, & Altman, 2009) The 
PRISMA checklist is provided in the Appendix 3.  
 
RESULTS 
Search results and study characteristics 
Figure 1 shows the study selection flow diagram. The literature search yielded 739 articles of which 29 
duplicate records were removed. An additional 672 articles were screened by their titles and abstracts, 
leaving  38 full-text articles selected for critical reading (kappa=0.72; good agreement). Twenty-seven 
did not meet the inclusion criteria as no relevant outcomes were reported (Appendix 4). Eleven studies 
yielding a total of 13 adherence estimates met the inclusion criteria and were included (kappa=1.00; 
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100% agreement) in the meta-analysis(Catz, Sosman, Scheuerell, & Crumble, 2002; N. E. Chen et al., 
2013; Chitsaz et al., 2013; Ines et al., 2008; Mostashari, Riley, Selwyn, & Altice, 1998; Palepu et al., 
2004; Paparizos et al., 2013; Perez et al., 2006; Soto Blanco, Perez, De Labry Lima, et al., 2005; Soto 
Blanco, Perez, & March, 2005; Wakoli, Baliddawa, Kimaiyo, & Braitstein, 2010). The sample was 
composed of 2895 HIV-infected prisoners on ART.  Table 1 presents the characteristics of the included 
studies.  The studies were carried out between 1992 and 2011 and reported between 1998 and 2013. 
Most were reported as journal articles (n=9, 82%); only two were presented as conference abstracts 
(18%). When reported the mean age of the participants ranged from 34.0 to 44.7 years and percentage 
drug users ranged from 32% to 100%. The preponderance of the studies (n=9, 82%) were cross-
sectional and two were cohort studies (18%). Most of the studies were conducted in high-income 
countries (n=10, 91%) and only one study was conducted in low-income country. Studies were carried 
out in the United States (n=4, 36%), Spain (n=4, 36%), Canada (n=1, 9%), Greece (n=1, 9%), and 
Kenya (n=1, 9%).  Most studies measured adherence using self-reported questionnaires (n=10, 91%) 
only one study used pharmacy refills.   Most of the studies used adherence threshold of 100% (n=8, 
73%) and three studies a threshold of ≥95% (n=3, 27%).  
 
Risk of bias of included studies 
The summary risk of bias of included studies is shown in Figure 2. All studies recruited participants 
from representative samples, selection bias due to sample population is low in all studies. Selection 
bias due to participation rate is low in five studies, i.e. participation rate was greater than >70-85% in 
these five studies and unclear in the remaining six studies. Performance bias due to outcome bias was 
in all the 11 studies, they all used subjective measures (self-reported questionnaires and pharmacy 
refill). Performance bias due to confounding was low in five studies that reported adjusted associations, 
high in two studies and unclear in the remaining four studies. The risk of bias due to other potential bias 
was low in four studies and unclear in the remaining seven studies. 
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Overall adherence to ART during and after pregnancy 
Proportion of prisoners who achieved adequate adherence levels and 95% CIs from individual studies 
with a pooled estimate are shown in Figure 3. The pooled ART adherence proportions for all studies 
yielded an estimate of 54.6% (95% CI 48.1 to 60.9%) of patients with adequate ART adherence 
(≥95%). The I2 statistics was 90.5%, indicating statistically significant heterogeneity among the studies. 
The contour-enhanced funnel plot of examination of publication bias is shown in eFigure 1. The funnel 
plot appears symmetric and shows no evidence of publication bias (P = 0.631 for Egger's regression 
asymmetry test). The results of leave-one-study-out sensitivity analyses showed that no study had 
undue influence on pooled adherence estimate (eFigure 2).  
   
Adherence to ART by different subgroups 
The results of subgroup analyses are shown in Figure 4. The pooled proportion of prisoners who 
achieved adequate adherence levels was significantly higher among cross-sectional studies than 
cohort studies (57.3% versus 38.1%, p-value for interaction = 0.0001); and was significantly higher 
among studies that used self-reported measures than the study that used pharmacy refill (56.3% 
versus 32.7%, p-value for interaction = 0.0001). However, there were no statistically significant 
differential proportion of prisoners that achieved adequate adherence levels by other subgroups: type of 
publication, study period, publication year, region, study size, and adherence threshold.  
 
Factors modifying adherence estimates as identified by meta-regression analyses 
Factors associated with adherence estimates and proportion of explained variability in adherence 
estimates as identified by univariable meta-regression analyses are shown in Table 2. Adherence 
estimates from cross-sectional studies were 94% statistically significantly higher than those from cohort 
studies (OR = 1.94, 95% CI 1.43 to 12.62); and adherence estimates from studies that used self-
reported measure were 2.4 times as higher as those from pharmacy refill measure (OR = 2.44, 95% CI 
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1.60 to 3.73). Contrary to expectation, for every 10% increase in percentage of drug-users included in 
the studies, the adherence estimates increased by 16% (OR = 1.16, 95% CI 1.10 to 1.29) (eFigure 3). 
Percentage of drug-users, study design and adherence measure explain 40.6%, 24.9% and 20.3% in 
between study variability in adherence rates respectively.  
 
Factors associated with adherence rates as reported in individual studies 
Seven studies reported factors associated with adherence estimates among prisoners (eFigure 3). The 
following facilitators of optimal adherence were reported: good patients-physician and peers’ 
relationship, active occupation inside prison, absence of HIV symptoms, good acceptance of treatment, 
and higher educational attainment. While the following barriers of optimal adherence were reported: 
depressed mood, no social support, ‘bad’ quality food/food insecurity, difficulty in taking medications, 
previous injecting drug use, active medical problems, alcohol use and younger age.  
 
DISCUSSION 
Main findings 
To our knowledge, this is the first systematic review and meta-analysis to summarize the available data 
regarding ART adherence among prison inmates and has brought together evidence from 11 studies 
incorporating 2,895 prison inmates on HIV treatment. We found that the pooled proportion of prison 
inmates with adequate (≥95%) ART adherence was only about 54.6%, which is still lower compared to 
other high-risk subgroups, such as HIV-infected drug users (60% [95% CI 52% to 68%], 38 
studies)(Malta, Magnanini, Strathdee, & Bastos, 2010), HIV-infected female sex workers (76% [95% CI 
68% to 83%], 4 studies)(Mountain et al., 2014), and HIV-infected adolescents (62% [95% CI 57% to 
68%], 50 studies)(S. H. Kim, Gerver, Fidler, & Ward, 2014). Interestingly, ART-adherence was twice as 
high among HIV-infected prisoners in whom adherence was self-reported, compared to those for whom 
adherence was determined from pharmacy re-fill records. While self-reports are a validated method for 
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measuring medication adherence(Nguyen, La Caze, & Cottrell, 2014), we cannot rule out the 
disproportionately larger number of studies using this tool, as opposed to using pharamacy-refill 
records, which may have biased this result in favour of the former. We also cannot rule out the potential 
for recall bias when using self-reported measures.  
 
Nonetheless, our findngs may have important public health implications. For instance, that only one out 
of two HIV-infected prisoners have optimal ART adherence levels, suggests that ART non-adherence 
constitutes a considerable public health burden, given potential consequences, notably antiretroviral 
treatment failure and AIDS-specific mortality. Moreover, our meta-analysis was based almost entirely 
on studies conducted in high-income countries. This potentially suggests that the pooled ART 
adherence prevalence obtained in our study may be underestimated because prison health services in 
low- and middle-income countries are less likely to be as comprehensive as prison health services in 
high-income countries, such that HIV-infected prisoners in the former may be more at risk of ART non-
adherence, compared to HIV-infected prisoners in the latter.  
 
Study limitations and strengths 
The results of this meta-analysis should be interpreted with caution. We found statistically significant 
heterogeneity across the studies, thus suggesting that the percentage of the variability in effect 
estimates that is due to heterogeneity rather than sampling error (chance) is important. A considerable 
proportion of the observed heterogeneity may be explained by differences in adherence thresholds, 
proportion of participants that were drug users and study design. Nevertheless, even in the presence of 
high heterogeneity, meta-analysis has been suggested as a preferred option for data synthesis 
compared to qualitative or narrative interpretation; narrative synthesis can lead to misleading 
conclusions that should not be generalized beyond the scope of the analysis(Ioannidis, Patsopoulos, & 
Rothstein, 2008). It is worth noting that the heterogeneity observed in the current study appears to be 
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the norm rather than the exception in published ART adherence meta-analyses(Falagas, Zarkadoulia, 
Pliatsika, & Panos, 2008; Peltzer & Pengpid, 2013). Another limitation is bias that can be introduced by 
the methods used for measuring adherence. Most of the studies included in this meta-analysis used 
self-reported adherence. Furthermore,  this is a conservative bias given that self-report may 
overestimate adherence, the actual levels of ART adherence may be even lower than what we are 
reporting. Finally, the meta-regression analysis has several limitations. Meta-regression represents an 
observational association and suffers from ecological fallacy(Thompson & Higgins, 2002). In addition, 
meta-regression has low statistical power to detect an association and easily influenced by an 
outlier(Lambert, Sutton, Abrams, & Jones, 2002). 
 
Despite these limitations, the study strengths are important. We conducted comprehensive searches of 
databases to ensure that all relevant, published studies were identified. We also conducted meta-
regression analyses to investigate whether any particular study-level factor explained the results and 
could account for the observed variations between studies. In doing so, we have comprehensively and 
robustly reviewed existing literature in this area, which points to key gaps in the current literature on 
determinants of ART adherence. 
 
CONCLUSION 
Our meta-analysis showed ART adherence among prison inmates is significantly below that 
recommended for adequate virologic suppression. Only about half of the prisoners achieved optimal 
adherence (54.6%). Optimal adherence remains a challenge in prisoners and it is crucial to monitor 
ART adherence, investigate specific risk factors for non-adherence among prisoners and develop 
appropriate interventions.  
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TABLES 
Table 1: Characteristics of included studies 
Author (year) Type of 
publication 
Study 
period 
Study 
design 
cou
ntry 
Income 
category 
Male 
(%) 
Mean 
age 
Drug 
users 
(%) 
Sampl
e size 
Adher
ence 
measu
re 
Adher
ence 
thres
hold 
Catz et al. 2002(Catz et al., 2002) Conference
e abstract 
Not 
reporte
d 
Cross-
sectional 
USA High-
income 
92 Not 
reporte
d 
Not 
reported 
50 Self-
reporte
d 
100 
Chen et al. 2013(N. E. Chen et al., 2013) Full-text 2007-
2010 
Cross-
sectional 
USA High-
income 
66.2 44.7 78.5 653 Self-
reporte
d 
95 
Chitsaz et al. 2013(Chitsaz et al., 2013) Full-text 2007-
2011 
Cross-
sectional 
USA High-
income 
72.3 42.8 72.3 1163 Self-
reporte
d 
95 
Ines et al. 2008(Ines et al., 2008) Full-text 1993-
1995 
Cross-
sectional 
Spai
n 
High-
income 
92 NR 72 50 Self-
reporte
d 
100 
Mostashari et al. 1998(Mostashari et al., 
1998) 
Full-text 1993-
1995 
Cross-
sectional 
USA High-
income 
0 35 90 102 Self-
reporte
d 
100 
Palepu et al. 2004(Palepu et al., 2004) Full-text 1997-
2002 
Cohort Can
ada 
High-
income 
90 34 44.6 101 Pharm 
Refills 
100 
Paparizos et al. 2013(Paparizos et al., 
2013) 
Full-text 2001-
2011 
Cohort Gre
ece 
High-
income 
90.3 37.45 32.2 93 Self-
reporte
d 
95 
Perez et al 2006(Perez et al., 2006) Full-text 2003 Cross-
sectional 
Spai
n 
High-
income 
88.7 35.7 Not 
reported 
160 Self-
reporte
d 
100 
Soto Blanco et al 2005 (a)(Soto Blanco, 
Perez, & March, 2005) 
Full-text 2000 Cross-
sectional 
Spai
n 
High-
income 
84.7 Not 
reporte
d 
100 177 Self-
reporte
d 
100 
Soto Blanco et al 2005 (b)(Soto Blanco, 
Perez, De Labry Lima, et al., 2005) 
Full-text 2002 Cross-
sectional 
Spai
n 
High-
income 
90 35.5 94 281 Self-
reporte
d 
100 
Wakoli et al. 2010(Wakoli et al., 2010) Conference
e abstract 
Not 
reporte
d 
Cross-
sectional 
Ken
ya 
Low-
income 
80 35 Not 
reported 
65 Self-
reporte
d 
100 
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Table 2: Factors associated with adherence estimates identified by meta-regression analyses 
Factors OR (95% CI) p-value R2 (%) 
Full-text (vs. abstract) 0.63 (0.25 to 1.62) 0.305 1.0 
Publication year 0.99 (0.92 to 1.06) 0.779 0.0 
Recent (vs. earlier) studies 1.10 (0.90 to 1.35) 0.310 1.7 
Cross-sectional (vs cohort) study 1.94 (1.43 to 2.62) 0.000 24.9 
American (vs European) study 1.05 (0.51 to 2.17) 0.888 0.0 
Male (%) 0.99 (0.98 to 1.01) 0.386 0.0 
Mean age (years) 1.03 (0.92 to 1.14) 0.553 0.0 
Drug-user (per 10% increase) 1.16 (1.10 to 1.29) 0.000 40.6 
Large (vs small) study 1.25 (0.65 to 2.45) 0.461 0.0 
100% (vs. 95%) threshold 1.07 (0.54 to 2.12) 0.836 0.0 
Self-reported (vs. pharm refill) 2.44 (1.60 to 3.73) 0.000 20.3 
  
FIGURE LEGENDS  
Figure 1: Study selection flow diagram 
 
  
Figure 2: Risk of bias included studies 
 
 
 
  
Figure 3: Pooled proportion of prison inmates’ adherent to antiretroviral therapy 
 
 
  
Figure 4: Pooled proportion of prison inmates’ adherent to antiretroviral therapy, by different sub-groups 
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APPENDICIES 
 
Appendix 1: Medline search strategy 
1     adherence.mp.  
2     nonadherence.mp.  
3     compliance.mp.  
4     noncompliance.mp.  
5     non-compliance.mp.  
6     "pill count?".mp.  
7     MEMS.mp.  
8     "medication event monitoring system".mp.  
9     "pharm* refil*".mp. 
10     exp Medication Adherence/ 
11     or/1-10  
12     "*prison*".mp.  
13     prisoner?.mp.  
14     imprison.mp.  
15     incarcerat*.mp.  
16     "*offend*".mp.  
17     "remand*".mp.  
18     "*detain*".mp.  
19     "*criminal*".mp.  
20     "*convict*".mp.  
21     "*felon*".mp.  
22     pre-trial.mp.  
23     under-trial.mp.  
24     "jail".mp.  
25     "gaol".mp.  
26     "detention".mp.  
27     "correction*".mp.  
28     "sentence*".mp.  
29     "probation*".mp.  
30     "parole*".mp.  
31     re-entry.mp.  
32     reentry.mp.  
33     "post-release".mp.  
34     "transition*".mp.  
35     "supervis*".mp.  
36     inmate?.mp.  
37     in-mate?.mp.  
38     "correctional facility".mp.  
39     exp prisoner/  
40     exp prison/  
41     exp criminal/  
42     exp detention/  
43     exp jail/  
44     exp parole/  
45     exp offender/  
46     or/12-45 
25 
 
47     (hiv or hiv or hiv-1 or hiv-2).mp.  
48     human immunodeficiency virus.mp.  
49     human immunedeficiency virus.mp.  
50     human immune-deficiency virus.mp.  
51     hiv infections.mp.  
52     aids.ti,ab.  
53     acquired immune-deficiency syndrome.mp.  
54     acquired immunedeficiency syndrome.mp.  
55     acquired immunodeficiency syndrome.mp.  
56     acquired immuno-deficiency syndrome.mp.  
57     (HAART or highly active anti?retroviral therapy or highly active anti retroviral therapy).mp.  
58     Antiretroviral Therapy.mp.  
59     retroviral*.mp.  
60     Antiviral Agents.mp.  
61     human immunodeficiency.mp.  
62     antiretroviral*.mp.  
63     exp hiv infections/  
64     exp human immunodeficiency virus/  
65     exp acquired immune-deficiency syndrome/  
66     exp acquired immunodeficiency syndrome/ 
67     exp acquired immuno-deficiency syndrome/  
68     exp hiv/ 
69     exp hiv-1/  
70     exp hiv-2/  
71     exp HIV SERONEGATIVITY/  
72     exp HIV SEROPOSITIVITY/  
73     exp HIV SEROPREVALENCE/  
74     exp HIV ANTIBODIES/  
75     exp ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE/  
76     exp Antiretroviral Therapy/  
77     or/47-76  
78     11 and 46 and 77  
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Appendix 2: Risk of bias assessment 
Bias type Adequate Inadequate Unclear 
Selection (sample 
population) 
Rationale for cases 
(prisoners) selection 
explained 
Sample selection 
ambiguous and sample 
unlikely to be 
representative 
Insufficient 
information 
Selection 
(participation rate) 
High participation rate (>70-
85%) 
Low participation rate 
(<70%) 
Insufficient 
information 
Performance bias 
(outcome 
assessment) 
Objective measures of 
adherence 
Self-reported measure of 
adherence 
Insufficient 
information 
Performance bias 
(analytical methods 
to control for bias) 
Analysis appropriate for type 
of sample (unadjusted, 
univariable analyses etc.) 
Analysis does not 
account for common 
adjustment (adjusted, 
multivariable analyses) 
Insufficient 
information 
Other form of bias There is no evidence of bias 
from other sources. 
There is potential bias 
present from other 
sources 
Insufficient 
information 
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Appendix 3: PRISMA checklist 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; 
objectives; data sources; study eligibility criteria, participants, and 
interventions; study appraisal and synthesis methods; results; limitations; 
conclusions and implications of key findings; systematic review registration 
number.  
2 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already 
known.  
3 
Objectives  4 Provide an explicit statement of questions being addressed with reference 
to participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
3 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., 
Web address), and, if available, provide registration information including 
registration number.  
NA 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used 
as criteria for eligibility, giving rationale.  
3 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, 
contact with study authors to identify additional studies) in the search and 
date last searched.  
4 
Search  8 Present full electronic search strategy for at least one database, including 
any limits used, such that it could be repeated.  
4 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included 
in systematic review, and, if applicable, included in the meta-analysis).  
4 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, 
independently, in duplicate) and any processes for obtaining and 
confirming data from investigators.  
5 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, 
funding sources) and any assumptions and simplifications made.  
5 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies 
(including specification of whether this was done at the study or outcome 
level), and how this information is to be used in any data synthesis.  
4 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in 
means).  
5-6 
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Section/topic  # Checklist item  
Reported 
on page #  
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if 
done, including measures of consistency (e.g., I2) for each meta-analysis.  
5-6 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative 
evidence (e.g., publication bias, selective reporting within studies).  
4 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup 
analyses, meta-regression), if done, indicating which were pre-specified.  
5-6 
RESULTS  
 
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in 
the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
6 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., 
study size, PICOS, follow-up period) and provide the citations.  
6-7 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome 
level assessment (see item 12).  
7 
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: 
(a) simple summary data for each intervention group (b) effect estimates 
and confidence intervals, ideally with a forest plot.  
7 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals 
and measures of consistency.  
7-8 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 
15).  
7 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup 
analyses, meta-regression [see Item 16]).  
8-9 
DISCUSSION  
 
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each 
main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
9 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at 
review-level (e.g., incomplete retrieval of identified research, reporting 
bias).  
10-11 
Conclusions  26 Provide a general interpretation of the results in the context of other 
evidence, and implications for future research.  
11 
FUNDING  
 
Funding  27 Describe sources of funding for the systematic review and other support 
(e.g., supply of data); role of funders for the systematic review.  
11 
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Appendix 4: Excluded studies 
 
Study  Reason 
Anonymous1 No relevant outcome reported 
Babudieri 20002 No relevant outcome reported 
Babudieri 20053 No relevant outcome reported 
Baillargeon 20004 No relevant outcome reported 
Baillargeon 20095 No relevant outcome reported 
Beckwith 20106 No relevant outcome reported 
Bird 19937 No relevant outcome reported 
De Groot 20068 Narrative review 
Fontana 20079 No relevant outcome reported 
Frank 199910 Narrative review 
Gallego 200311 No relevant outcome reported 
Gir 200512 No relevant outcome reported 
Kantrowitz 200513 No relevant outcome reported 
Karus 200714 No relevant outcome reported 
Pai 200915 No relevant outcome reported 
Pontali 200516 Narrative review 
Roberson 200917 No relevant outcome reported 
Saberi 201218 No relevant outcome reported 
Scheyett 200819 No relevant outcome reported 
Seal 200520 Narrative review 
Small 200921 No relevant outcome reported 
Spaulding 200922 No relevant outcome reported 
Springer 2004 23 No relevant outcome reported 
Springer 2005 24 Narrative review 
Springer 201125 Narrative review 
Westergaard 2011 26 No relevant outcome reported 
White 2006 27 No relevant outcome reported 
 
1. Mean streets: out of prison, out of HIV med compliance. Prisoner re-entry needs targeted 
focus. (2009). AIDS alert, 24(7), 73-75.  
2. Babudieri, S., Aceti, A., D'Offizi, G. P., Carbonara, S., & Starnini, G. (2000). Directly observed 
therapy to treat HIV infection in prisoners. JAMA, 284(2), 179-180.  
3. Babudieri, S., Pintus, A., Maida, I., Starnini, G., & Rezza, G. (2005). Does counseling increase 
sustained benefit of HAART among prison inmates after release to the community? Clinical 
Infectious Diseases, 40(2), 321-322; author reply 322-323.  
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4. Baillargeon, J., Borucki, M. J., Zepeda, S., Jenson, H. B., & Leach, C. T. (2000). Antiretroviral 
prescribing patterns in the Texas prison system. Clinical Infectious Diseases, 31(6), 1476-
1481. doi:10.1086/317478 
5. Baillargeon, J., Giordano, T. P., Rich, J. D., Wu, Z. H., Wells, K., Pollock, B. H., & Paar, D. P. 
(2009). Accessing antiretroviral therapy following release from prison. JAMA, 301(8), 848-857.  
6. Beckwith, C. G., Zaller, N. D., Fu, J. J., Montague, B. T., & Rich, J. D. (2010). Opportunities to 
diagnose, treat, and prevent HIV in the criminal justice system. Journal of Acquired Immune 
Deficiency Syndromes: JAIDS, 55 Suppl 1, S49-55. 
7. Bird, A. G., Gore, S. M., Burns, S. M., & Duggie, J. G. (1993). Study of infection with HIV and 
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8. De Groot, A. S., Dilorenzo, M., Sylla, M., & Bick, J. (2006). Challenges and opportunities for 
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173-191.  
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eFigure 2: Leave-one-out sensitivity analyses 
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eFigure 3: Association between percentage drug users and adherence rate 
among prison inmates 
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eFigure 4: Overview of factors associated with adherence as reported by 
individual studies 
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